Careers  |  Sign In  |  Register

Dr. Chen on the Impact of the Pivotal IMpower133 Trial on SCLC

Hui-Zi Chen, MD, PhD, assistant professor in the Department of Internal Medicine, Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center – James, discusses the future of atezolizumab as a new FDA-approved first-line treatment for metastatic small cell lung cancer. Dr. Chen explains the addition of atezolizumab to the platinum-based standard of care results in better median overall survival compared with controls receiving only platin-based chemotherapy.

Learn more by clicking here.